60
Participants
Start Date
February 28, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
OTR4132
OTR4132 is a new ReGeneraTing Agent (RGTA®) which is a polymer of glucose (α-1,6 bounds, i.e. dextran backbone) engineered to mimic heparan sulphate (HS) in all three mechanical functions (extracellular matrix scaffold element, protector of matrix pro-teins and cellular communication peptides storage sites) but differ from HS by their resistance to glycanases. OTR4132 allows a restoration of the matrix architecture which secondarily facilitates cell survival and recovery at the site of injury.
Placebo
saline solution
Hôpitaux Universitaires De Marseille Timone-AP-HM, Marseille
Centre hospitalier universi-taire de Brest (Cavale Blanche), Brest
Centre Hospitalier Universi-taire de Bordeaux-Hôpital Pellegrin, Bordeaux
Centre Hospitalier Universitaire Grenoble Alpes, Grenoble
UIC Imagerie et Neurovasculaire CHU de Nantes, Nantes
Centre Hospitalier Régional Universitaire de Nancy, Nancy
Centre Hospitalier Régional Universitaire de Lille- Hôpital Roger Salengro, Lille
Hôpital de Hautepierre, Strasbourg
Hôpital de la Pitié Salpêtrière - AP-HP, Paris
Hôpital Fondation Adolphe de Rothschild Service de neuro-vasculaire, Paris
Hôpital Foch, Suresnes
CHU Henri-Mondor, Créteil
Centre Hospitalier Universitaire de la Guadeloupe, Pointe à Pitre
Centre Hospitalier Universitaire de Martinique, Fort de France
GHU Paris Psychiatrie & Neurosciences, Paris
Collaborators (1)
Euraxi Pharma
INDUSTRY
Organ, Tissue, Regeneration, Repair and Replacement
INDUSTRY